BioSpace News Archive

As previously announced on January 14, Masimo (NASDAQ: MASI) will release fourth quarter and full year 2019 financial results for the period ended December 28, 2019, after the market closes on Wednesday, February 19, 2020

CONMED Corporation announced that Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 10:30 a.m. ET on Wednesday, February 26, 2020 in New York, NY.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) seeking approval for ripretinib, the Company’s investigational broad-spectrum KIT and PDGFRα inhibitor, for the treatment of patients with advanced gastrointestinal stromal tumors (GIST).

Signaling a dedication to further strengthen its unique corporate culture, CooperCompanies President and CEO Albert White has signed the CEO Action for Diversity & Inclusion™ pledge.

Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2019 financial results will be released on Tuesday, February 25, 2020 after the markets close.

Fellowship-trained breast surgeon Katrina Mitchell, MD, IBCLC, FACS, is joining forces with University of Massachusetts-Amherst cancer researchers on a study that will examine breast milk from nursing women who have a pathogenic BRCA1 or BRCA2 genetic mutation

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2020 to report its fourth quarter and full year 2019 financial results,

Elanco Animal Health Incorporated announced it has signed an agreement to divest the European Economic Area and UK rights to the Drontal® and Profender® product families from Bayer AG’s animal health business, to Vetoquinol SA, a French pharmaceutical company, for $140 million in an all-cash deal subject to customary post-closing adjustments.

AVEO Oncology (NASDAQ: AVEO) today announced the publication of results from a monotherapy trial of tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in patients with advanced, inoperable hepatocellular carcinoma (HCC) in the British Journal of Cancer.

Survey by Travel Leaders Network assesses impact of coronavirus on leisure travel bookings